|
Most effective VS least effective DMP*
|
Incremental costs
|
Incremental QALYs
|
Mean ICER
|
% of 5000 simulated ICERs per quadrant in the CE plane
|
---|
| | | | |
NW
|
NE
|
SW
|
SE
|
---|
Health care perspective
| | | | | | | | |
CVR-primary#
|
7 VS 4
|
−534
|
0.003
|
−178,539
|
1
|
3
|
41
|
56
|
(297)
|
(0.021)
|
CVR-secondary$
|
1 VS 3
|
−671
|
0.012
|
−56,809
|
6
|
21
|
15
|
58
|
(976)
|
(0.015)
|
CVR-both
|
2 VS 8
|
−721
|
0.005
|
−148,480
|
2
|
2
|
35
|
61
|
(416)
|
(0.016)
|
COPD
|
1 VS 4
|
1,716
|
0.009
|
185,747
|
33
|
46
|
11
|
10
|
(2,000)
|
(0.053)
|
DMII
|
1 VS 3
|
−677
|
0.013
|
−50,234
|
1
|
3
|
14
|
82
|
(398)
|
(0.013)
|
Societal perspective
| | | | | | | | |
CVR-primary#
|
7 VS 4
|
−1,131
|
0.003
|
−377,991
|
5
|
12
|
37
|
46
|
(1,334)
|
(0.021)
|
CVR-secondary$
|
1 VS 3
|
−153
|
0.012
|
−12,929
|
10
|
36
|
11
|
43
|
(1,225)
|
(0.015)
|
CVR-both
|
2 VS 8
|
−604
|
0.005
|
−124,457
|
6
|
8
|
31
|
55
|
(554)
|
(0.016)
|
COPD
|
1 VS 4
|
2,054
|
0.009
|
−222,314
|
34
|
47
|
11
|
9
|
(2,371)
|
(0.053)
|
DMII
|
1 VS 3
|
−1,735
|
0.013
|
−128,790
|
1
|
2
|
14
|
83
|
(1,084)
|
(0.013)
|
- *most effective is defined based on the highest incremental QALY and the reverse; #primary prevention for CVD; $secondary prevention for CVD; ICER: incremental cost-effectiveness ratio; CE: cost-effective(ness); best is defined as most effective based on QALYs and worse as the least effective based on the same measurement; the numbers correspond to the DMP numbers in Table 4.